ProQR Therapeutics - הכנסה לפני ניכוי ריבית, מסים ופחת PRQR

ProQR Therapeutics N.V. (PRQR) is actively scaling RNA editing innovations to combat hereditary pathologies. The GURU.Markets terminal displays the company's absolute operating profit in cash terms, where 0.00 represents the current metric value. Growth is driven by alliances with pharma behemoths and patent licensing, as well as the Axiomer platform and the monetization of intellectual property.

This indicator captures the daily inflow of actual cash from core operations, allowing for an assessment of current liquidity and operational resilience without accounting for accruals. By analyzing EBITDA dynamics, an investor can see the actual cash flow, which is critically important for ProQR Therapeutics (PRQR) when funding the development of the Axiomer platform and preparing clinical data in partnership with pharma behemoths.